Carboplatin

Suppliers by country/region

• India(79)
• China(256)
• United States(71)
• Germany(11)
• United Kingdom(24)
• Europe(3)
• The Netherlands(2)
• Japan(3)
• Switzerland(4)
• South Korea(3)
• Belgium(2)
• Canada(6)
• Slovenia(1)
• Argentina(5)
• Philippines(1)
• France(2)
• Israel(3)
• Czech Republic(2)
• Poland(1)
• Uruguay(1)
• Greece(1)
• Nigeria(1)
• Austria(1)
• Brazil(5)
• Venezuela(1)

Company Type

• Manufacturer
• Reagent
• Trader
• Service provider
• Service

Properties

Safety Information

Use

Carboplatin, cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II), is a second-generation platinum drug. Its structure is based on cisplatin with the difference that the chloride ligands are exchanged for a bidentate chelating ligand. A consequence is that carboplatin is less reactive than cisplatin and therefore is less nephrotoxic and orthotoxic than the parent compound. Unfortunately, it is more myelosuppressive than cisplatin, which reduces the patients’ white blood cell count and makes them susceptible to infections. Carboplatin was licensed by the FDA in 1989 under the brand name Paraplatin and has since then gained worldwide recognition. Carboplatin on its own or in combination with other anticancer agents is used in the treatment of a variety of cancer types including head and neck, ovarian, small-cell lung, testicular cancer and others. Carboplatin is a pale-white solid showing good aqueous solubility. The synthesis starts with potassium tetrachloroplatinate, which is reacted to the orange [PtI4]2- anion.